

Full-text available at http://www.ajbrui.com http://www.bioline.br/md http://www.ajol.com

**Received**: October 2006

Accepted February 2007

Published May 2007 Full Length Research Article

# Effect of Melatonin on Carbon Tetrachloride-Induced Kidney Injury in Wistar Rats

# Stephen O. Adewole<sup>1\*</sup>, Abdulkadir A. Salako<sup>2</sup>, Oladepo W. Doherty<sup>3</sup> and Thajasvarie Naicker<sup>4\*</sup>

Department of <sup>1\*</sup>Anatomy and Cell Biology, <sup>2</sup>Surgery, <sup>3</sup>Chemistry Faculty of Basic Medical Sciences, College of Health Sciences; Obafemi Awolowo University, Ile-Ife, Nigeria; <sup>4\*</sup>Optics and Imaging Centre, Nelson R Mandela Medical School, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa.

# ABSTRACT

Exposure to carbon tetrachloride ( $CCl_4$ ) induces acute and chronic renal injuries as well as oxidative stress in rats. The aim of this study was to evaluate the effect of exogenous melatonin (MEL) treatment on CCl<sub>4</sub>-induced oxidative stress and nephrotoxicity in rats using histopathological and biochemical parameters. Serum creatinine, blood urea nitrogen (BUN), nitrite and albumin concentrations were measured for the evaluation of renal function. Antioxidant status in the kidney tissue was estimated by determining the activities of superoxide dismustase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT) and glutathione-S-transferase (GST) as well as thiobarbituric acid reactive substances (TBARS) and reduced glutathione (GSH) levels. For histopathological evaluation, kidney of all rats were excised and processed for light microscopy. CCl<sub>4</sub> caused elevated level of TBARS and marked depletion of renal endogenous antioxidant enzymes. Furthermore, severe deterioration of renal function was observed in CCl<sub>4</sub>-treated rats as assessed by increased serum creatinine, BUN levels and decreased creatinine and urea clearance as compared with the control rats. MEL treatment positively ameliorated the alterations in these biochemical variables in the  $CCl_{4}$  + MEL-treated rats. MEL markedly reduced elevated TBARS and nitrite, significantly attenuated renal dysfunction, increased the levels of antioxidant enzymes. Kidney sections of  $CCl_4$ -treated group showed, changes in microanatomy. In contrast, these deleterious histopathological alterations resulting from CCl<sub>4</sub> nephrotoxin were absent after MEL treatment in CCl<sub>4</sub> + MEL group of rats. In conclusion, our results demonstrated that MEL through its antioxidant activity effectively ameliorated CCl<sub>4</sub>induced nephrotoxicity.

(Afr. J. Biomed. Res. 10: 153 - 164)

**Keywords:** Carbon tetrachloride; Melatonin; Nephrotoxicity; Renal dysfunction; Antioxidants

\*Address for Correspondence: stephenadewole@yahoo.co.uk

#### Abstracted by:

African Index Medicus (WHO), CAB Abstracts, Index Copernicus, Global Health Abstracts, Asian Science Index, Index Veterinarius, Bioline International, African Journals online

#### INTRODUCTION

The pathogenesis of Carbon tetrachloride (CCl<sub>4</sub>)induced renal dysfunction is not completely known. It may be due to the functional state of liver, or renal injury may develop independently to hepatic events (Rincon *et al.*, 1999). CCl<sub>4</sub> induces oxidative stress in many settings (Abraham *et al.*, 1999); therefore, it might be expected to contribute to nephrotoxicity. CCl<sub>4</sub> does not occur naturally, it is a clear liquid with sweet smell that can be detected at low levels (Doherty, 2000). Exposure to various compounds including a number of environmental pollutants and drugs can cause cellular damages through metabolic activation of those compounds to a highly reactive oxygen species (ROS).

Free radical induced lipid peroxidation is believed to be one of the major causes of cell membrane damage leading to a number of pathological situations (Slater, 1984). CCl<sub>4</sub> was formerly used for metal degreasing and as drycleaning, fabric-spotting, and fire extinguisher fluids, grain fumigant and reaction medium. Because of its harmful effects, these uses are now banned and it is only used in some industrial applications (DeShon, 1979). The primary routes of potential human exposure to CCl<sub>4</sub> are inhalation, ingestion, and dermal contact. High exposure to CCl<sub>4</sub> can cause liver, kidney and central nervous system damage, and liver is especially sensitive to CCl<sub>4</sub> because of its role as the body's principal site of metabolism (Sakata et al., 1987). Reports from our laboratory and other investigators have established that CCl<sub>4</sub> is a potent environmental hepatotoxin (Szymonik-Lesiuk et al., 2003).

A number of reports clearly demonstrated that in addition to hepatic toxicity,  $CCl_4$  also causes disorders in kidneys, lungs, testis as well as in blood by generating free radicals (Ahmad *et al.*, 1987; Ozturk *et al.*, 2003). Findings by Perez *et al.*, (1987), Ogeturk *et al.*, (2005) and Churchill *et al.*, (1983) suggested that exposure to this solvent causes acute and chronic renal injuries. In addition, report on various documented case studies established that  $CCl_4$  produces renal diseases in human (Ruprah *et al.*, 1985; Gosselin *et al.*, 1984). A number of endogenous and exogenous nephropathy risk factors generate oxygen free radicals *in vivo*. Therefore the

role of oxygen-derived free radicals and lipid peroxidation has attracted considerable attention (Gebhardt, 2002; Das et al., 2005). Volatile organic compounds such as CCl<sub>4</sub> are a class of solvents to which many people are exposed occupationally and environmentally. Early studies of dichloromethane, 1,1-dichloroethylene  $CCl_4$ and revealed susceptibility of rats to liver and kidney damage by these chemicals (Bruckner et al., 1984). It has been found that metabolism of CCl<sub>4</sub> involves in the production of free radicals through its activation by drug metabolizing enzymes located in the endoplasmic reticulum (Slater and Sawyer, 1971). Therefore, it has become a task to prevent nephropathy and hepatic damage by eliminating free radicals and prevent lipid peroxidation through the use of terminal antioxidant like melatonin (Esrefoglu et al., 2005).

Cumulative data suggest a role for reactive oxygen metabolites as one of the postulated mechanisms in the pathogenesis of CCl<sub>4</sub> nephrotoxicity (Recknagel et al., 1989). CCl<sub>4</sub> results in enhanced generation of trichloromethylperoxyl radical (Cl<sub>3</sub>COO<sup>-</sup>), hydrogen peroxide in cultured hepatocytes as well as mesangial cells (Knight et al., 1989). In vitro and in vivo studies indicate that CCl<sub>4</sub> enhances lipid peroxidation, reduces renal microsomal NADPH cytochrome P450, and renal reduced/oxidiced glutathione ratio (GSH/GSSG) in kidney cortex as well as renal microsomes and mitochondria (Rungby and Ernst, 1992). Antioxidants such as melatonin, ascorbate, atocopherol, silibinin, lazaroid, propinonyl carnitine and superoxide dismutase/catalase, have been shown to ameliorate CCl<sub>4</sub>-induced renal toxicity (Miller and Rice, 1997).

Nitric oxide (NO) is a free radical formed from the terminal guanidine group of L-arginine by enzymatic reaction involving NO synthase (NOS). NO is one of the principal mediators involved in the pathogenesis on inflammatory responses partly through direct effects on nuclear factor  $\kappa B$  (NF $\kappa B$ ). Endogenous inducible NO synthase (iNOS)-derived NO has a protective role in proteinuric tubulointerstitial injury, but excess production has adverse effects in the same situation. Among its multiple divergent functions, NO has several antiinflammatory properties. Apart from maintaining perfusion on the renal microcirculation, NO inhibits leukocytes and platelet endothelial adhesion (Radomski *et al.*, 1987), suppresses T-cell and monocyte proliferation and preserves integrity of the vascular endothelial permeability barrier (Suttorp *et al.*, 1996). NO also is a physiologically important scavenger of superoxide radicals, been more potent than superoxide dismutase (Rubanyi *et al.*, 1991).

Mammalian cells are equipped with both enzymic and non-enzymic antioxidants defenses with different efficacies that protect animals against oxidative abuse caused by wide range of nephrotoxicants including CCl<sub>4</sub> (Karbownik et al., 2001). Melatonin, N-acetyl-5-methoxytrptamine is a hormone found in all living creatures from algae (Caniato et al., 2003) to humans, at levels that vary in a diurnal cycle. In higher animals MEL is produced by pinealocytes in the pineal gland. Melatonin participates in many important physiological functions, including anti-inflammatory (Cuzzocrea and Reiter, 2002), also, it is a powerful antioxidant that can easily cross cell membranes and the blood-brain barrier (Hardeland, 2005). Unlike other antioxidants, MEL does not undergo redox cycling, once oxidized; it cannot be reduced to its former state because it forms several stable endproducts upon reacting with free radicals (Tan et al., 2000). Redox cycling may allow other antioxidants such as vitamin C to act as pro-oxidants, counterintuitively promoting free radical formation. Furthermore, MEL has been demonstrated to prevent damage to DNA by some carcinogens, stopping the mechanism by which they cause cancer (Karbownik et al., 2001; Carrillo-Vico et al., 2005). Melatonin is an immunomodulatory agent that enhances T-cell production and when taken in conjunction with calcium, it is a potent immunostimulator of the Tcell response (Vijayalaxmi et al., 2002). It holds the unique position of being the only known chronobiotic regulator of neoplastic cell growth. Both in vitro and in vivo, MEL has been found to inhibit neoplastic growth and to delay tumor progression (Tan et al., 1993). In addition, MEL protects liver and kidney injury induced by endotoxin shock and ischemia/reperfusion in rats through its antioxidant action (Sener et al., 2003).

Beneficial effects of exogenous MEL on vital organs like brain, liver, kidney and lungs as well as

cardiovascular system have been largely reviewed (Zenebe *et al.*, 2001). Therefore, the present study was designed to (i) evaluate beneficial effect of exogenous melatonin in preventing acute renal dysfunction/nephrotoxicity induced by CCl<sub>4</sub> in rats, and (ii) analyze degree of kidney injury via antioxidative mechanisms

## MATERIALS AND METHODS

Animal care and monitoring: This study was carried out in healthy, male and female Wistar rats, weighing 240-260 g. The animals were housed under standard laboratory conditions of light, temperature  $(21\pm2^{\circ}C)$  and relative humidity (55±5%). The animals were given standard rat pellets and tap water ad libitum. The rats were randomly divided into four experimental groups: A (control), B (CCl<sub>4</sub>), C (CCl<sub>4</sub> + MEL) and D (MEL), each group consisted of 10 rats. The experimental protocol and procedures used in this study were approved by the Ethics Committee of the University of KwaZulu-Natal, Durban 4000, South Africa; and conform with the "Guide to the Care and Use of Animals in Research and Teaching" [Published by the Ethics Committee of the University of Durban-Westville, Durban 4000, South Africa].

Experimental design: Animals were divided into four groups of ten rats each. Group A rats were treated with olive oil in quantities equivalent to the of CCl<sub>4</sub> and MEL administered volume subcutaneously. The rats in groups B and C were treated with CCl<sub>4</sub> (1 ml/kg body weight, s.c.) in a 1:1 solution with olive oil. The rats in group C were additionally treated with MEL (5 mg/kg/, s.c.) for 3 days prior to administration of CCl<sub>4</sub>; and MEL treatment was continued for further 8 weeks at alternate days. Melatonin was dissolved in (9 g/L) saline with absolute ethanol (</=0.1 ml/L) and stored at -20°C until used. Group D rats received MEL (5 mg/kg/, s.c.) treatment for a period of 8 weeks, at alternate days. All the animals were fasted for 16 hours, but still allowed free access to water, before the commencement of our experiments. At the end of experimental period of 8 weeks, the animals were sacrificed by cervical dislocation; serum/plasma samples and liver tissue were

collected and stored at -80°C for analysis.

Kidney histopathology: Kidney tissues were excised from sacrificed animals, individually weighed, and thin kidney slices were cut, fixed in 4% paraformaldehyde and were sequentially embedded in paraffin wax blocks. Tissue sections of 5 µm thick were cut, and stained with hematoxylineosin (H-E) and masson's trichrome (Suzuki and Suzuki, 1998) for conventional morphological evaluation, then examined under light microscope (BX50; Olympus, Tokyo). The images were obtained by a digital camera system (Pixcera Co., Osaka, Japan) attached to the microscope. A minimum of 10 fields for each kidney slide were examined and scored semiguantitatively for severity of changes by a pathologist unaware of the type of treatment. The scoring was done as none (-), mild (+), moderate (++) and severe (+++).

**Determination of Creatinine (Cr) and BUN levels** and clearances ( $C_{cl}$ ): Before sacrifice, rats were kept individually in metabolic cages (TP-85M; Toyoriko, Tokyo). After 4-5 days adaptations to the cage, urine samples were collected in ice-cooled glass flasks every 8 h for 24 h and stored at 4°C. Urine samples from each rat were combined and measured. After centrifugation, aliquots of the supernatant were frozen at -40°C. Rats were sacrificed under light anesthesia with halothane by decapitation. The abdomen was opened by transverse incision and kidneys were excised for histological studies and enzymatic analysis. Blood samples were collected by cardiac puncture into heparinized container. BUN values as indicators of renal damage were determined by the NADHcoupled enzymatic method, using urase spectrophotometrically in an enzyme-based assay (Hallett and Cook, 1971). Urine and serum samples assayed for were creatinine. using а spectrophotometric assay method of Junge et al., (1998). For the assay, urine was diluted 1:50 in distilled water. Three microliters plasma or diluted urine and 300 µl picric acid reagent (consisting of saturated aqueous picric acid diluted 5-fold in 0.25 M NaOH) were dispensed in duplicate, using a MicroLab dilutor (Hamilton, Reno, NV) into wells of a microtiter plate. After incubation for 15 min at

room temperature, absorbance was read at 515 nm in a microplate reader. Creatinine clearance was calculated according to Cockcroft-Gault formular (Cockcroft and Gault, 1976).  $C_{cr} = (C_u/C_s) \times V$ , where  $C_u$  is the concentration of creatinine in urine,  $C_s$  is the concentration of creatinine in serum and V is the urine flow rate in milliliters per minute.

**Serum and Urine albumin concentration:** Serum albumin concentration was measured in a multistat III Plus machine with reagents from Fisher Scientific (St. Louis, MO). Urine samples were collected into test tubes and stored at -40°C for analysis. The concentration of urinary albumin was determined using standard diagnostic kits, an enzyme-linked immunosorbent assay (ELISA) (Nephrat Exocell Inc., Philadelphia, PA, USA).

Assessment of urine/serum and tissue nitrite concentration: Urine samples were deproteinized by equal volumes of 0.3M NaOH and 5% zinc sulphate and centrifuged at 6400 x g for 20 min. The supernatants were added in duplicates to 96-well plates and reacted with Greiss reagent (1:1 solution of 1% sulphanilamide in 5% phosphoric acid and 0.1% napthaylamine diamine dihydrochloric acid in water). Also serum and tissue nitrite was estimated using Greiss reagent and served as an indicator of NO production. 500 µl of Greiss reagent was added to suitably diluted 100 µl of serum and supernatant of the tissue as described above and corrected by protein amount. Nitrite levels were assessed by measurement of absorbance at 540 nm using a micro plate reader (Model 550; Bio-Rad laboratories, Hercules, CA) (Green et al., 1982). Nitrite concentration was calculated using a standard curve for sodium nitrite. Nitrite levels were expressed as µmol/ml in serum and urine and as µmol/mg protein in homogenate.

**Preparation of tissue homogenate:** The harvested kidney tissues were rinsed in cold physiological saline, cleaned of gross adventitial tissue, blotted dry and stored in a Biofreezer at  $-80^{\circ}$ C until analyzed. Liver tissue was homogenized with Potter Elvehjem homogenizer. 10% homogenates were prepared in 6.7 mM phosphate buffer, pH 7.4 and centrifuged at 10,000 rpm for 10 min at 4°C, and the resultant supernatant was used for measurement of

antioxidant enzymes. For the determination of lipid peroxidation, liver tissue was homogenized in 1.15% KCl solution to obtain a 10% (w/v) homogenate. Protein content of liver homogenates was determined by using bicinchoninic acid (BCA) protein assay reagent (Pierce Chemical Company, Rockford, IL). All enzyme activities were expressed as units/mg protein.

#### **Biochemical assays:**

Superoxide Dismutase Activity (SOD): Kidney SOD activity was assayed by the method of Kakkar *et al.*, (1984). Reaction mixture contained 1.2 ml of sodium pyrophosphate buffer (0.052 mM, pH 7.0), 0.1 ml of phenazine methosulphate (PMS) (186  $\mu$ M), 0.3 ml of nitro blue tetrazolium (NBT) (300  $\mu$ M). 0.2 ml of the supernatant obtained after centrifugation (1500 x g, 10 min followed by 10,000 x g, 15 min) of 10% kidney homogenate was added to reaction mixture. Enzyme reaction was initiated by adding 0.2 ml of NADH (780  $\mu$ M) and stopped precisely after 1 min by adding 1 ml of glacial acetic acid. Amount of chromogen formed was measured by recording color intensity at 560 nm. Results are expressed as units/mg protein.

Glutathione Peroxidase Activity (GSH-Px): Glutathione peroxidase (GSH-Px) activity was measured by NADPH oxidation, using a coupled system consisting of glutathione, reaction glutathione reductase, and cumene hydroperoxide (Tappel, 1978). 100 µL of enzyme sample was incubated for five minutes with 1.55 ml stock solution (prepared in 50 mM Tris buffer, pH 7.6 with 0.1 mM EDTA) containing 0.25 mM GSH, 0.12 mM NADPH and 1 unit glutathione reductase. The reaction was initiated by adding 50 µL of cumene hydroperoxide (1 mg/ml), and the rate of disappearance of NADPH with time was determined by monitoring absorbance at 340 nm. One unit of enzyme activity is defined as the amount of enzyme that transforms 1 µmol of NADPH to NADP per minute. Results are expressed as units/mg protein.

**Catalase Activity (CAT):** The activity of CAT was measured using its perioxidatic function according to the method of Johansson and Borg, (1988).  $50 \,\mu\text{L}$ potassium phosphate buffer (250 mM, pH 7.0) was incubated with 50  $\mu$ l methanol and 10  $\mu$ L hydrogen peroxide (0.27%). The reaction was initiated by addition of 100 µL of enzyme sample with continuous shaking at room temperature (20°C). After 20 minutes, reaction was terminated by addition of 50 µL of 7.8 M potassium hydroxide. 100 µL of purpald (4-Amino-3-hydrazino-5mercapto-1,2,4-triazole, 34.2 mM in 480 mM HCl) was immediately added, and the mixture was again incubated for 10 minutes at 20°C with continuous shaking. Potassium peroxidate (50 µL 65.2 mM) was added to obtain a colored compound. The absorbance was read at 550 nm in а spectrophotometer. Results are expressed as micromoles of formaldehyde produced/mg protein.

**Reduced glutathione (GSH):** Reduced glutathione (GSH) level in the kidney was assayed following the method of Ellman (1959), modified by Hissin and Hilf (1973). The homogenate (720  $\mu$ l) was double diluted and 5% TCA was added to it to precipitate the protein content of the homogenate. After centrifugation (10, 000 x g for 5 minutes) at 4°C the supernatant was taken, 5,5'-dithiolbis-2-nitrobenzoic acid (DTNB) solution (Ellmam's reagent) was added to it and the absorbance was measured at 412 nm on a spectrophotometer. A standard graph was drawn using different concentrations of standard GSH solution (1 mg/ml). With the help of the standard graph, GSH contents in the homogenates of the experimental animals were calculated.

**Glutathione-S-transferase (GST):** GST catalyzes the conjugation reaction with glutathione in the first step of mercapturic acid synthesis. GST activity was measured by the method of Habig and Jakoby (1974). The reaction mixture contained suitable amount of the enzyme (25  $\mu$ g of protein in homogenates), 1 ml of KH<sub>2</sub>PO<sub>4</sub> buffer, 0.2 ml of EDTA, 0.1 ml of 1-chloro-2,4-dinitrobenzene (CDNB), and GSH. The reaction was carried out at 37°C and monitored spectrophotometrically by the increase in absorbance of the conjugate of GSH and CDNB at 340 nm. A blank was run in absence of the enzyme. One unit of GST activity is 1 µmol product formation per minute.

**Thiobarbituric**Acid**ReactiveSubstances**(**TBARS**):The product of the reaction between

malondialdehyde (MDA) and thiobarbituric acid reactive substances (TBARS) were measured by the method of Ohkawa et al., (1997). The reaction mixture consisted of 0.2 ml of 8.1% sodium lauryl sulphate, 1.5 ml of 20% acetic acid solution adjusted to pH 3.5 with sodium hydroxide and 1.5 ml of 0.8% aqueous solution of thiobarbituric acid was added to 0.2 ml of 10% (w/v) of homogenate. The mixture was brought to 4.0 ml with distilled water and heated at 95°C for 60 minutes. After cooling with tap water, 1.0 ml distilled water and 5.0 ml of the mixture of n-butanol and pyridine (15:1 v/v) was added and centrifuged at 3000 rpm for 10 minutes. The organic layer was taken out and absorbance of the clear upper (n-butanol) layer was measured using Shimadzu UV-1601 (Japan) spectrophotometer at 532 nm. TBARS were quantified using an extinction coefficient of 1.56 x 10<sup>5</sup> cm<sup>-1</sup> M<sup>-1</sup> and expressed as nmol of TBARS/mg tissue protein. Tissue protein was estimated using Biuret method of protein assay and the renal MDA content expressed as nmol of MDA per mg protein.

**Statistical Analysis:** The data obtained were expressed as means ( $\pm$ SEM). The inter-group variation was measured by one way analysis of variance (ANOVA; 95% confidence interval) followed by Fischer's LSD test. Statistical significance was considered at p<0.05.

# RESULTS

**Body and kidney weights:** Table 1 shows the changes in body and kidney weights of all experimental animal groups. Administration of  $CCl_4$  significantly increased (p<0.05) kidney weight and

19.8±1.6

at the same time significantly decreased body weight when compared with the control and MEL-treated groups of rat. MEL treatment significantly (p < 0.05) reduced relative kidney weight, and produced a statistically near equal (p = 248.3) body weight with the body of control rats. The CCl<sub>4</sub> + MEL group insignificantly showed changes in kidney and body weights (Table 1).

Histopathological findings: CCl<sub>4</sub> administration alone caused prominent histopathological damage in the kidney compared with the control rats. The histopathological changes were graded and summarized (Table 2). The kidney sections from the control- and MEL-treated groups showed normal glomeruli, and tubulointerstitial cells (Plate 1A and 1D). In contrast, the kidneys of CCl<sub>4</sub>-treated rats showed marked deleterious histological changes. The kidney sections showed significant glomerular and tubular degenerations varying from, glomerular basement thickening, interstitial inflammation, tubular cell swelling, pycnotic nuclei, medullary vascular congestion and moderate to severe necrosis (Plate 1B). MEL-treated group of rats preserved normal morphology of the kidney and shows normal architecture of the kidney (Plate 1C).

**Urine/Serum and tissue nitrite levels:** Administration of  $CCl_4$  significantly increased (p<0.05) urine, serum and tissue nitrite levels in  $CCl_4$ -treated rats. Melatonin treatment significantly decreased (p<0.05) the elevated nitrite levels in urine, serum and tissue of  $CCl_4$ +MEL-treated rats. However MEL *per se* has no effect on urine, serum and tissue nitrite levels of group D rats (Table 3).

20.7±2.1

enanges in couj and manej	in engines of e office	$\beta$ , $\varepsilon$ $\varepsilon$ $\epsilon$ , $\varepsilon$ $\epsilon$ $\epsilon$ , $\varepsilon$ $\epsilon$ $\epsilon$	, and the areated ta	is und armarj
Parameters	Control	CCl <sub>4</sub>	CCl <sub>4</sub> + MEL	MEL
Body weights (g)	256.4±7.2	223.8±9.1 <sup>a</sup>	248.3±5.6	254.9±3.6
Kidney weights (g)	0.98±0.82	1.36±0.75 <sup>b</sup>	1.02±0.14	0.83±0.42

 $11.5 \pm 1.4^{c}$ 

 $Changes in body and kidney weights of control, CCl_{4^-}, CCl_{4^-} + MEL-, and MEL-treated rats and urinary volume per day.$ 

Values are expressed as means ( $\pm$ SEM) of 8 rats for all groups. <sup>*a,b,c*</sup> Significant difference (p<0.05) in the same row between various treatments and control group A rats.

 $16.2\pm2.3$ 

# Table 2.

Urinary volume (ml/day)

Table 1.

Effect of MEL treatment on morphological changes as assessed by histopathological examination of kidneys of rats

exposed to CCl <sub>4</sub> .						
Groups	Tubular cell swelling	Interstitial inflammation	Tubular dilatation	Necrosis of epithelium	Glomerular hypercellularity	
Control	-	-	-	-	-	
$CCL_4$	+ + +	+ + +	+ + +	+ + +	+ + +	
$CCl_4 + MEL$	+/	+/	+/-	+/	+/	
MEL	_	_	_	_	_	

to CCI

Severity of renal histological changes using scores on a scale of none (-), mild (+), moderate (++) and severe (+++) damage.

<b>Table 3.</b> Changes in nitrite levels in the urine, serum and kidney	y tissue homogenates of exp	perimental animal groups.	
--	-----------------------------	---------------------------	--

Variables	Control	CCl <sub>4</sub>	$CCl_4 + MEL$	MEL
Urine nitrite (µmol/ml)	2.56±1.24	23.16±2.43 <sup>a</sup>	8.89±1.72	$1.94{\pm}1.80^{b}$
Serum nitrite (µmol/ml)	59.92±5.34	$97.30 \pm 8.52^{a}$	66.74±5.62	$61.88 \pm 6.47^{b}$
Tissue nitrite (µmol/mg)	107.21±2.29	192.64±7.36 <sup>a</sup>	112.35±9.16	$102.43 \pm 5.84^{b}$

Values are expressed as means (±SEM) of 8 rats. <sup>a</sup>Statistical significant at P<0.05 as compared to control, <sup>b</sup>Statistical significant at P<0.05 as compared to CCl<sub>4</sub>-treated.

Table 4. Assessment of renal functions in the experimental animal groups treated with CCl<sub>4</sub> and MEL.

Parameters	Control	CCl <sub>4</sub>	$CCl_4 + MEL$	MEL
Serum creatinine (mg/dl)	0.68±0.04	$2.78 \pm 0.05^{a}$	$0.82 \pm 0.02$	$0.64 \pm 0.03^{b}$
Urine creatinine (mg/dl)	57.2±1.29	$96.4{\pm}1.36^{a}$	63.8±1.12	$56.1 \pm 1.84^{b}$
Serum urea (mg/dl)	24.50±1.6	$87.20{\pm}2.1^{a}$	18.70±1.2	$15.80 \pm 0.38^{b}$
Urine urea (mg/dl)	92.4±28.0	$124.1\pm6.0^{a}$	97.2±25.0	90.3±27.0 <sup>b</sup>
Urine albumin (g/dl)	14.8±1.9	$35.4 \pm 3.5^{a}$	18.9±1.6	$12.1 \pm 1.7^{b}$
Serum albumin (g/dl)	28.5±3.7	$15.8 \pm 4.9^{a}$	24.7±5.2	30.6±1.9 <sup>b</sup>
Creatinine clearance (ml/min)	1.16±0.07	$0.48{\pm}0.06^{a}$	1.04±0.03	$1.13 \pm 0.04^{b}$
Urea clearance (ml/min)	1.52±0.15	$0.32\pm0.24^{a}$	1.22±0.14	$1.49\pm0.21^{b}$

Values are expressed as means ( $\pm$ SEM) of 8 rats. <sup>a</sup>Statistical significant at P<0.05 as compared to control, <sup>b</sup>Statistical significant at P<0.05 as compared to CCl<sub>4</sub>-treated.

Serum creatinine, BUN and albumin levels: CCl<sub>4</sub> treatment significantly increased (p<0.05) the serum creatinine, BUN and urine albumin levels as compared with the control group of rats. However, serum albumin levels were significantly lower in CCl<sub>4</sub>-treated rats (Table 4). Although, treatment of rats with MEL significantly prevented this rise in serum creatinine, BUN and urine albumin and at the same time increased serum albumin in CCl<sub>4</sub> + MEL group of rats (Table 4). Creatinine and urea clearance, which was markedly decreased in CCl<sub>4</sub>treated rats, was significantly increased by MEL treatment (Table 4). MEL treatment per se, however, had no effect on these biochemical variables in group D rats (Table 4).

melatonin on biochemical variables in the tissue homogenates of all experimental animal groups. administration CCl₄ markedly decreased antioxidants enzymes as well as glutathione levels and this is suggestive of oxidative stress in CCl<sub>4</sub>treated rats. There was clear evidence that CCl<sub>4</sub>induced renal injury was associated with free radical injury and oxidative stress as evidenced by the activities antioxidants activities (Table 5). Oxidative stress was characterized by increased lipid peroxidation and/or altered non-enzymatic and enzymatic antioxidant systems.

Biochemical findings: Table 5 shows the effects of

#### Table 5.

Changes in the activities of SOD, GSH-Px, CAT, GST, and levels of GSH and TBARS in kidney homogenates of experimental animal groups

Parameters	Control	CCl <sub>4</sub>	CCl <sub>4</sub> + MEL	MEL
SOD (U/mg protein)	$110.14 \pm 0.4$	$59.71 \pm 0.5^{a}$	92.36±0.6	113.28±0.4 <sup>b</sup>
GSH-Px (µmol/mg protein)	33.27±0.29	17.34±0.46 <sup>a</sup>	29.35±0.12	$34.04 \pm 0.85^{b}$
CAT (µmol/mg protein)	76.53±0.62	44.28±0.71 <sup>a</sup>	69.76±0.26	$78.80 \pm 0.38^{b}$
GST (µmol/mg protein)	$1.48\pm0.42$	$0.62 \pm 0.92^{a}$	1.10±0.16	$1.60\pm0.26^{b}$
GSH (µg/mg protein)	26.14±0.87	12.64±0.56 <sup>a</sup>	19.32±0.76	$27.24 \pm 0.96^{b}$
TBARS (nmol/mg protein)	93.18±1.85	$153.12{\pm}1.24^{a}$	102.72±1.64	89.36±1.57 <sup>b</sup>
				1.

Values are expressed as means ( $\pm$ SEM) of 8 rats. <sup>a</sup>Statistical significant at P<0.05 as compared to control, <sup>b</sup>Statistical significant at P<0.05 as compared to CCl<sub>4</sub>-treated.



**Plate 1.** Photomicrographs of kidney sections stained with hematoxylin-eosin and masson's trichrome under light microscope. (A) Control rats showing normal rat kidney with normal tubular brush-borders (T) and intact glomeruli (G). No evidence of congestion or inflammation was observed in the sinusoid. (B) CCl<sub>4</sub>-treated rats showing tubular brush-borders loss, interstitial oedema (O), glomerular hypercellularity (H), necrosis of epithelium (N) and inflammatory cells infiltration. (C) CCl<sub>4</sub> + MEL-treated rats showing attenuated necrosis, reduced inflammatory cells and improved tubule and glomeruli architecture. (D) MEL-treated rats showing normal morphology of kidney. Bar = 100µm

Effects of  $CCl_4$  and  $CCl_4 + MEL$  treatments on renal tissue's SOD, GSH-Px, CAT, GST, GSH and TBARS are presented in Table 5. The renal

antioxidant activity of SOD, GSH-Px, CAT, GST and GSH significantly decreased (p<0.05), while renal TBARS significantly increased in the CCl<sub>4</sub>treated, group of rats. The control group of rats maintained optimal value activity of the antioxidants studied. Administration of melatonin significantly (p<0.05) decreased the elevated TBARS, and also significantly increased (p<0.05) the reduced antioxidant enzyme activities. Furthermore, MEL proved significantly better in restoring the altered activity of antioxidant enzymes like SOD, GSG-Px, CAT, GST, GSH and TBARS towards their normal values in the kidney homogenates. The animals treated with MEL alone showed no significant change in the levels of GSH and in the activities of GST related enzymes (Table 5).

#### DISCUSSION

In vitro and in vivo studies indicate that CCl<sub>4</sub> enhances lipid peroxidation, reduces renal microsomal NADPH cytochrome P450, and renal reduced/oxidized glutathione ratio (GSH/GSSG) in kidney cortex as well as renal microsomes and mitochondria (Walker et al., 1996). In general, a number of chemicals including various environmental toxicants and even clinically useful drugs can cause severe cellular damages in different organs of the body through metabolic activation to highly reactive substances such as free radicals (Noguchi *et al.*, 1982).  $CCl_4$  is one of such widely used environmental toxicant to experimentally induce animal models of acute nephrotoxicity and

#### Abstracted by:

African Index Medicus (WHO), CAB Abstracts, Index Copernicus, Global Health Abstracts, Asian Science Index, Index Veterinarius, Bioline International, African Journals online hepatic damages. CCl<sub>4</sub> is metabolized by cytochrome P450 2E1 to trichloromethyl radical  $(CCl_3)$ .  $CCl_3$  and its highly reactive derivative, the trichloromethylperoxyl radical (Cl<sub>3</sub>COO<sup>-</sup>), are assumed to initiate free radical-mediated lipid peroxidation leading to accumulation of lipid peroxidation products that causes renal and hepatic injuries (Aleynik et al., 1997). These radicals are capable of initiating a chain of lipid peroxidation abstracting reactions by hydrogen from polyunsaturated fatty acids (PUFA). Peroxidation of lipids, particularly those containing PUFA, can dramatically change the properties of biological membranes, resulting in severe cell damage and play a significant role in pathogenesis of diseases (Aleynik et al., 1997). This phenomenon results in the generation of ROS, (like superoxide anion  $O_2^-$ ,  $H_2O_2$  and hydroxyl radical OH<sup>-</sup>).

Evidence suggests that various enzymatic and non-enzymatic systems have been developed by mammalian cells to cope with ROS and other free radicals (Recknagel et al., 1989). However, when a condition of oxidative stress establishes, the defense capacities against ROS becomes insufficient (Halliwell and Gutteridge, 2000). ROS also affects the antioxidant defense mechanisms, by reducing the intracellular concentration of GSH and decreases the activity of SOD, CAT and GSH-Px. It has also been observed to decrease the detoxification system produced by GST (Yamamoto and Yamashita, 1999). In the kidney GST is a cystolic protein, highly specific for the cells of the proximal tubules. It is found in high concentrations and is readily released into the urine in the event of renal tubular injury (Harrison et al., 1989). Oxidative stress can promote the formation of a variety of vasoactive mediators that can affect renal function directly by initiating renal vasoconstriction or decreasing the glomerular capillary ultrafiltration coefficient; and thus reducing glomerular filtration rate (Garcia-Cohen et al., 2000). Thus the attenuation of lipid peroxidation in CCl<sub>4</sub>-treated rats by MEL provides a convincing evidence for the involvement of ROS in CCl<sub>4</sub>-induced lipid peroxidation.

It is a known fact that MEL, the chief secretory product of the pineal gland, was found to be a multifaceted free radical scavenger and antioxidant. It detoxifies a variety of free radicals and reactive oxygen intermediates, including the hydroxyl radical, singlet oxygen peroxynitrite anion and nitric oxide (Tan et al., 2002). In both in vitro and in vivo experiments, MEL has been found to protect cells, tissues, and organs against oxidative damage induced by a variety of free-radical-generating agents and processes, such as the CCl<sub>4</sub>, ischemia reperfusion, amyloid-protein, carcinogen safrole and ionizing radiation (Marchiafava and Longoni, 1999). Melatonin also has been reported to stimulate the activities of enzymes and increase gene expression that improves the total antioxidative defense capacity of the organism such as SOD, GSH-Px, and GSH (Kotler et al., 1998). Recent studies indicate that MEL is effective on inhibiting oxidative and kidney and liver damage (Calvo et al., 2001). Melatonin also could dose-dependently reduce kidney lipid peroxide content in CCl<sub>4</sub>-treated rats. This indicated that MEL exerted a therapeutic effect on CCl<sub>4</sub>-induced acute or chronic renal injury in rats, possibly through its antioxidant action. Melatonin plays a cytoprotective role in the kidney insulted by ischemia and reperfusion by virtue of its ability to prevent kidney malfunction and inhibit the generation of free radicals and accumulation of neutrophils in the damaged renal tissue (Lepay et al., 1985).

From the present study, it has been observed that CCl<sub>4</sub> induced significant decrease in SOD, CAT, GSH-Px and GST activities, depleted the GSH content and enhanced lipid peroxidation in kidney. It has been reported that SOD, CAT, GSH-Px and GST constitute a mutually supportive team of defense against ROS (Bandhopadhy et al., 1999). The decreased activity of SOD in kidney in CCl<sub>4</sub>treated rats may be due to the enhanced lipid peroxidation or inactivation of the antioxidative enzymes. This would cause an increased accumulation of superoxide radicals, which could further stimulate lipid peroxidation. GST bind to liophilic compounds and acts as an enzyme for GSH conjugation reactions (Anadan et al., 1999). Decreased GST activity during CCl<sub>4</sub> toxicity might be due to the decreased availability of GSH resulted enhanced lipid peroxidation. during the Administration of MEL prior to CCl<sub>4</sub> intoxication protected the antioxidant machineries of the kidney as revealed from enhanced levels of SOD, CAT,

GSH-Px and GST activities, increased GSH content and decreased lipid peroxidation.

NO production has been reported to increase in renal disease (Cattell *et al.*, 1990), our results confirm these findings. Nitrite excretion in urine was increased in CCl<sub>4</sub>-treated rats and significantly diminished by MEL treatment. In addition, decreased nitrite content in kidney tissue was observed to be significant. However, increased NO in urine might be due to an increased NO production in the glomeruli as a result of changes in L-arginine utilization or an additional activation of systemic macrophages. Also it is possible that NO directly mediates hyperfilteration through its potent vasodilatory properties which is in agreement with findings of Reyes *et al.* (1992).

The present study revealed that chronic administration of CCl<sub>4</sub> caused marked impairment in renal function alongside with significant oxidative stress in the kidney. Serum creatinine and BUN concentrations were significantly higher in CCl<sub>4</sub>treated rats which are consistent with lower creatinine and BUN clearance. MEL significantly improved creatinine and BUN clearance, and decreased the elevated levels of serum creatinine and BUN. In addition, elevated level of urinary albumin and reduced level of serum albumin concentrations in CCl<sub>4</sub>-treated rats might have resulted from remarkable leakage due to hypercellularity of both glomeruli and tubules (Fig. 4B). Histopathological alterations common to CCl<sub>4</sub>-treated rats were glomerular hypercellularity, moderate to severe necrosis and tubulointerstitial alterations. It is believed that the capacity for tubular absorption may have been altered, thus bringing about functional overload of nephrons with subsequent renal dysfunctions (Fig. 4B). On the other hand, MEL protect kidney tissue against oxidative damagesinduced by CCl<sub>4</sub>

In conclusion this study demonstrates that melatonin through its marked antioxidant activity coupled with favourable anti-inflammatory effects salvages  $CCl_4$ -induced nephrotoxicity.

#### ACKNOWLEDGEMENTS

The authors are grateful to Mr. O. Adeogun, Mr. J Ibeh and Miss K. Moodley for their technical assistance in tissue processing.

#### REFERENCES

Abraham P., Wilfred G., Catherine S. P. (1999): Oxidative damage to the lipids and protein in the lungs, testis and kidney of rats during carbon tetrachloride intoxication. Clin Chim Acta., 289: 177-179.

Ahmad F. F., Cowan D. L., Sun A. Y. (1987): Detection of free radical formation in various tissues after acute carbon tetrachloride administration in gerbil. Life Sci., 41: 2469-2475.

Aleynik S. I., Leo M. A., Ma X., Aleynik M. K., Lieber C. S. (1997): Polyenylphospha tidycholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol 27: 554-561.

Anadan R., Deepa Rekha R., Devaki T. (1999): Protective effect of Picrorrhiza Kurroa on mitochondrial glutathione antioxidant systems in D-galactosamine induced hepatitis in rats, 76: 1543-1545.

**Bandhopadhy U., Das D., Banerjee K. R. (1999): Reactive oxygen species:** Oxidative damage and pathogenesis. Curr Sci., 77: 658-665.

**Bruckner J. V., Luthra R., Kyle G. M.,** *et al.* (1984): Influence of time of exposure to carbon tetrachloride on toxic liver injury. Annu Rev Chronopharmacol 1: 373-376.

**Calvo J. R., Reiter R. J., Garcia J. J., Ortiz G. G., Tan D. X., Karbownik M. (2001):** Characterization of the protective effects of melatonin and related indoles against alpha-naphthylisothiocyanate-induced liver injury in rats. J Cell Biochem., 80: 461-470.

Caniato R., Filippini R., Piovan A, *et al.* (2003): "Melatonin in plants". Adv Exp Med Biol 527: 593-597. Carrillo-Vico A., Guerrero J., Lardone P., Reiter R. (2005): A review of the multiple actions of melatonin on the immune system. Endocrine, 27(2): 189-200.

**Cattell V., Cook T., Moncada S. (1990):** Glomeruli synthesize nitrite in experimental nephrotoxic nephritis Kidney Int 38: 1056-1060.

**Churchill D. N., Finn A., Gault M. (1983):** Association between hydrocarbon exposure and glomerulonephritis. An araisal of the evidence. Nephron 33: 169-172.

Cockcroft D. W., Gault M. H. (1976): Prediction of creatinine from serum creatinine. Nephron, 16: 31-41.

**Cuzzocrea S., Reiter R. J. (2002):** Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2: 153-165.

**Das S., Santra A., Lahiri S., Guha Mazumder D. N.** (2005): Implications of oxidative stress and hepatic cytokine (TNF- $\alpha$  and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol., 204: 18-26.

**DeShon N. D. (1979):** Carbon tetrachloride. Kirk-Othmer Encyclopedia of Chemical Technology, 3<sup>rd</sup> ed. Grayson M, and Eckroth D, eds. New York: John Wiley and Sons, Inc. 5:704-714. [as cited by Santodonato J. 1985. Monograph on human exposure to chemicals in the workplace: CCl<sub>4</sub>; PB86-143377].

**Doherty R. E. (2000):** "A history of the production and use of Carbon Tetrachloride Tetrachloroethylene and 1,1,1-Trichloroethane in the US: Part 1, 1: 69-81.

**Ellman G. L. (1959):** Tissue sulfhydryl group. Arch Biochem Biophys, 82: 70-77.

**Esrafoglu M., Gul M., Emre M. H., Polat A., Selimoglu M. A. (2005):** Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats. World J Gastroenterol., 1959; 11: 1951-1956.

Garcia-Cohen E. C., Marin J., Diez-Picazo L. D., Baena A. B., Salaices M., Rodriguez-Martinez M. A. (2000): Oxidative stress induced by tertbutylhydroperoxide causes vasoconstriction in the aorta from hypertensive and aged rats: role of cyclooxygenase-2 isoform J Pharmacol Exp Ther 293(1): 75-81.

**Gebhardt R. (2002):** Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment. Phytother Res., 16: 368-372.

**Gosselin R. E., Smith R. P., Hodge H. C. (1984):** Clinical toxicology of commercial products. 5<sup>th</sup> edition. Williams and Wilkins and Wilkins, Baltimore, MD.

**Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S., Tannenbaum S. R. (1982):** Analysis of nitrite, nitrite, and [<sup>15</sup>N]nitrite in biological fluids. Anal Biochem., 126: 131-138.

Habig W. H., Jakoby W. B. (1974): Glutathione Stransferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139.

Hallett C. J., Cook J. G. H. (1971): Reduced nicotinamide adenine dinucleotide-coupled reaction for emergency blood urea estimation. Clin Chim Acta 35: 33-37.

Halliwell B., Gutteridge J. M. C. (2000): Free radicals in Biology and medicine. Oxford University Press, pp. 148-149.

**Hardeland R. (2005):** "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine, 27(2): 119-130.

**Harrison D. J.**, *et al.* (1989): Glutathione S-transferase isoenzymes in the human kidney: Basis for possible biomarkers of renal injury J Clin Pathol., 42: 624-629.

*Hissin P. J., Hilf R. (1973):* A fluorometric method for the determination of oxidized and reduced glutathione in tissue, Anal. Biochem., 74: 214-226.

Johansson L. H., Borg L. A. (1988): A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem. 174:

331–336.

Junge W., Wilke B., Halabi A., Klein G. (2004): Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with enzymatic and a modified Jaffe method. Clin Chim Acta 344: 137-148.

Karbownik M., Reiter R., Cabrera J., Garcia J. (2001): Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat Res., 474: 87-92. Karbownik M., Lewinski A., Reiter R. J. (2001): Anticarcinogenic action of melatonin which involves antioxidative processes: Comparison with other antioxidants. The Int J Biochem Cell Biol., 33: 735-743.

Kakkar P., Das B., Viswanathan P. N. (1984): A modified spectrophotometeric assay of superoxide dismutase. Ind Biochem Biophys., 21: 130-132.

Knight J. A., Cheung A. K., Pieper R. K., Servilla K. (1989): Increased urinary lipoperoxide levels in renal transplant patients. Ann Clin Lab Sci., 19: 238-241.

Kotler M., Rodriguez C., Sainz R. M., Antolin I., Menendez-Pelaez A. (1998): Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res., 24: 83-89.

Lepay D. A., Nathan C. F., Steinman R. M., Murray H. W., Cohn Z. A. (1998): Murine Kupfer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med., 161: 079-1096.

Marchiafava P. L, Longoni B. (1999): Melatonin as an antioxidant in retinal photoreceptors. J Pineal Res., 26: 184-189.

Miller N. J., Rice-Evans C. A. (1997): The relative contribution of ascorbic acid and phenolic antioxidants to the total antioxidant activity of orange and apple fruit juices and blackcurrant drink. Food Chem., 60: 331-337.

Noguchi T., Fong K. L., Lai E. K., Alexander S. S., King M. M., Olson L., Poyer J. L., Mccay P. B. (1982): Specificity of aphenobarbital-induced cytochrome P450 for metabolism of carbon tetrachloride to the trichromethyl radical. Biochem Pharmacol., 31: 615-624.

**Ogeturk M., Kus I., Colakoglu N., Zararsiz I., Ilhan N., Sarsilmaz M. (2005):** Cafeic acid phenethyl ester protects kidneys against carbon tetrachloride toxicity in rats. J Ethnopharmacol 97: 273-280.

**Ohkawa H., Ohishi N., Yagi K. (1979):** Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem., 95: 351-358.

Ozturk F., Ucar M., Ozturk I. C., Vardi N., Batcioglu K. (2003): Carbon tetrachloride –induced nephrotoxicity and protective effect of betaine in Sprague-Dawley rats. Urology 62: 353-356.

Perez A. J., Courel M., Sobrado J., Gonzalez L.

(**1987**): Acute renal failure after topical application of carbon tetrachloride. Lancet 1: 515-516.

**Radomski M. W., Palmer R. M., Moncada S. (1987):** Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058.

Recknagel R. O., Glende E. A., Dolak J. A., Waller R. L. (1989): Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther., 43: 139-154.

**Reyes A. A., Martin D., Settle S., Klahr S. (1992):** EDRF role in renal function and blood pressure of normal rats and rats with obstructive nephropathy Kidney Int., 41: 403-413.

**Rincon A. R., Covarrubias A., Pedraza-Chaverri J., Poo J. L., Armendariz-Borunda J., Panduro A. (1999):** Differential effect of CCl4 on renal function in cirrhotic rats. Exp Toxicol Pathol., 51: 199-205.

Rubanyi G. M., Ho E. H., Cantor E. H., Lumma W. C., Botelho L. H. P. (1991): Cytoprotective function of nitric oxide: Inactivation of superoxide radicals produced by human leukocytes Biochem Biophys Res Commun 181: 1392-1397.

**Rungby J., Ernst E. (1992):** Experimentally induced lipid peroxidation after exposure to chromium, mercury or silver: interactions with carbon tetrachloride. Pharmacol Toxicol 70(3): 205-207.

**Ruprah H., Mant T. G. K, Flanagan R. J. (1985):** Acute carbon tetrachloride poisoning in 19 patients: implications for diagnosis and treatment. Lancet 1: 1027-1029.

Sakata T., Watanabe N., Hobara N., Nagashima H. (1987): Chronic liver injury in rats by CCl<sub>4</sub> inhalation. Bull Environ Contam. Toxicol., 38: 959-961.

**Slater TF, Sawyer BC. (1971):** The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reaction in rat liver fractions in vitro. Inhibitory effects of free radical scavengers and other agents. J Biochem., 123: 823-828.

**Slater T. F. (1984):** Free radical mechanism in tissue injury. J Biochem., 222: 1-15.

Sener G., Tosun O., Sehirli A. O., Kacmaz A., Arbak S., Ersoy Y., Ayanoglu-Dulger G. (2003): Melatonin and N-acetycysteine have beneficial effects during hepatic ischemia and reperfusion. Life Sci., 72: 2707-2718.

Suttorp N., Hippenstiel S., Fuhrmann M., Krull M., **Podzuweit T. (1996):** Role of nitric oxide and phosphodiestrase isoenzyme II for reduction of endothelial hyper –permeability Am J Physiol., 270: C778-C785.

**Suzuki H., Suzuki K. (1998):** Rat hypoplastic kidney (*hpk/hpk*) induces renal anemia, hyperparathyroidism, and osteodystrophy at the end stage of renal failure. J Vet Med Sci., 60: 1051-1058.

Szymonik-Lesiuk S., Czechowska G., Stryjecka-Zimmer M., Slomka M., Madro A., Celinski K., Wielosz M. (2003): Catalase, superoxide dismutase and glutathione peroxidase activities in various rat tissues after carbon tetrachloride intoxication. J Hepatobilliary Pancreat Surg 10: 309-315.

Tan D. X, Poeggeler B., Reiter R. I, *et al.* (1993): The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett., 70: 65-71.

**Tan D. X., Manchester L., Reiter R.,** *et al.* (2000): "Significance of melatonin in anti oxidative defense system: reactions and products". Biol Signals Recept 9(3-4): 137-159.

Tan D. X., Reiter R. J., Manchester L. C., Yan M. T., EL-Sawi M., Sainz R. M., Mayo J. C., Kohen R., Allegra M., Hardeland R. (2002): Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem., 2: 181-197.

**Tappel A. L. (1978):** Glutathione peroxidase and hydroperoxides. Methods Enzymol. 52: 506–513

Vijayalaxmi Thomas C. R., Jr, Reiter R. J., Herman T. S. (2002): Melatonin: From basic research to cancer treatment clinics. J Clin Oncol., 10: 2575-2601.

Walker G., Kunz D., Pignat W., Wiesenberg I., Van den **Bosch H., Pfeilschifter J. (1996):** Tetranactin inhibits interleukin-1 $\beta$  and cAMP induction of group II phospholipase A2 in rat renal messangial cells. Eur J Pharmacol 306(3): 265-270.

**Yamamoto Y., Yamashita S. (1999):** Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. BioFactors, 9: 241-145.

**Zenebe W., Pechanova O., Bernatova I. (2001):** Protective effects of red wine polyphenolic compounds on the cardiovascular system. Exp Clin Cardiol., 6: 153-158.